Study Comparing Complete Versus Culprit-Only PCI in Patients with NSTEMI and Multivessel Coronary Artery Disease
Led by Leipzig Heart Science gGmbH · Updated on 2025-01-16
3390
Participants Needed
58
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether performing percutaneous coronary intervention PCI on all significant blockages in patients with non-ST-segment elevation myocardial infarction NSTEMI and multivessel coronary artery disease is better than treating only the main culprit lesion. This open-label, randomized, controlled, multicenter trial aims to compare these two approaches to understand which provides better outcomes for patients with this heart condition.
Participants will be randomly assigned to one of two groups. One group will receive optimal medical therapy and PCI only on the culprit lesion, with no further intervention on other blockages unless certain emergency criteria occur. The other group will receive complete revascularization of all significant non-culprit lesions, either during the initial procedure, hospitalization, or within 45 days after the initial PCI.
During the study, participants will be followed for an average of two years to monitor outcomes including cardiovascular death, rehospitalization for heart attacks, and other heart-related events. Researchers will also assess quality of life and complications such as bleeding, stroke, and kidney injury at various time points. The study involves regular evaluations and aims to gather comprehensive data to determine the best treatment strategy for these patients.
CONDITIONS
Brief Title
Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI
Research Team
H
Holger Thiele, MD, Prof. Dr.
H
Hans-Josef Feistritzer, MD, PhD; Assoc. Prof.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with non-ST-segment elevation myocardial infarction (NSTEMI) as suggested by high-sensitivity troponin tests
Have multivessel coronary artery disease
Have an identifiable culprit lesion for treatment
Able and willing to provide informed consent
You will not qualify if you...
Under 18 years of age
Currently experiencing cardiogenic shock
Have sustained ventricular tachycardia or ventricular fibrillation
Have contraindications for coronary revascularization
Have had prior coronary artery bypass graft surgery
Have indication for coronary artery bypass graft surgery
Have non-culprit lesion located in the left main coronary artery
Have a co-morbidity with life expectancy less than 6 months
Diagnosed with type 2 myocardial infarction
Are pregnant or breastfeeding
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 45 days after initial PCI
Participants receive percutaneous coronary intervention (PCI) for the culprit lesion. Some participants will also receive complete revascularization of all significant non-culprit lesions either during the initial procedure, during the initial hospital stay, or within 45 days after the culprit lesion PCI.
1 to 3 visits depending on revascularization timing
Follow-up
Duration - Up to 2 years
Participants are monitored for cardiovascular outcomes and safety measures after completing PCI treatment.
Regular follow-up visits over 2 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
National Prospective Registry Evaluating the Inspiron EVO Drug-Eluting Stent for Complex Coronary Lesions
Study Comparing Complete Versus Culprit-Only PCI in Patients with NSTEMI and Multivessel Coronary Artery Disease
Clinical Outcomes Study of Patients with Complex Three-Vessel or Left Main Coronary Artery Disease Following CCTA and FFRCT-Guided Coronary Bypass Surgery
Investigating Multi-Vessel Coronary Artery Disease and Angina
Using Balloon Occlusion and Symptom Assessment
Sponsored by Imperial College London
Comparing Stenting and Surgery for Multivessel and Left Main Coronary Artery Disease in Patients With Non-ST Elevation Acute Coronary Syndrome
STICH3C Observational Study Using Cardiac Magnetic Resonance Imaging
To Predict Outcomes After Heart Revascularization in Ischemic Left Ventricular Dysfunction
Comparing Surgery and Percutaneous Procedures for Patients with Reduced Heart Function and Multivessel Coronary Artery Disease
Safety and Effectiveness of the iVAC 2L Transaortic Device for Temporary Mechanical Circulatory Support
During High-risk Percutaneous Coronary Intervention in Adults
Study Comparing FAST Technique Guided PCI Versus Standard Treatment in Patients With STEMI and Multivessel Coronary Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
Hans-Josef Feistritzer, Alexander Jobs, Uwe Zeymer...